TY - JOUR
T1 - MIB guides
T2 - [89Zr]Zr-DFO-trastuzumab and [64Cu]Cu-NOTA-Trastuzumab for Preclinical Cancer Imaging
AU - Simó, Cristina
AU - Vanover, Alexander C.
AU - Azevedo, E. Carmen
AU - Pereira, Patrícia M.R.
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to World Molecular Imaging Society 2025.
PY - 2025/8
Y1 - 2025/8
N2 - Radiopharmaceuticals based on antibody biomolecules are widely used in oncology for positron emission tomography (PET). Trastuzumab, an antibody that targets the epidermal growth factor receptor 2 (HER2), has been extensively studied for both preclinical and clinical cancer imaging. This MIB guide specifically focuses on the radiolabeling of the antibody trastuzumab with zirconium-89 (89Zr) and copper-64 (64Cu) for PET imaging. The guide describes the steps for conjugating trastuzumab with p-SCN-Bn-deferoxamine (DFO) or 2,2',2''-(1,4,7-triazacyclononane-1,4,7-triyl)triacetic acid (p-SCN-Bn-NOTA) chelators through conjugation between the isothiocyanate (-SCN) functional group on the chelator with lysines on the trastuzumab. We also describe subsequent radiolabeling steps with 89Zr or 64Cu. The steps described here can be adapted to the radiolabeling of other antibodies upon protocol optimization.
AB - Radiopharmaceuticals based on antibody biomolecules are widely used in oncology for positron emission tomography (PET). Trastuzumab, an antibody that targets the epidermal growth factor receptor 2 (HER2), has been extensively studied for both preclinical and clinical cancer imaging. This MIB guide specifically focuses on the radiolabeling of the antibody trastuzumab with zirconium-89 (89Zr) and copper-64 (64Cu) for PET imaging. The guide describes the steps for conjugating trastuzumab with p-SCN-Bn-deferoxamine (DFO) or 2,2',2''-(1,4,7-triazacyclononane-1,4,7-triyl)triacetic acid (p-SCN-Bn-NOTA) chelators through conjugation between the isothiocyanate (-SCN) functional group on the chelator with lysines on the trastuzumab. We also describe subsequent radiolabeling steps with 89Zr or 64Cu. The steps described here can be adapted to the radiolabeling of other antibodies upon protocol optimization.
KW - Antibodies
KW - Copper-64
KW - Positron Emission tomography (PET)
KW - Radioimmunoconjugates
KW - Zirconium-89
UR - https://www.scopus.com/pages/publications/105009347908
U2 - 10.1007/s11307-025-02022-3
DO - 10.1007/s11307-025-02022-3
M3 - Article
C2 - 40571804
AN - SCOPUS:105009347908
SN - 1536-1632
VL - 27
SP - 506
EP - 517
JO - Molecular Imaging and Biology
JF - Molecular Imaging and Biology
IS - 4
ER -